Author(s):
Kale Digvijaysinh Ramesh, Khedkar Amol Navnath, Pawar Jaydeep Babasaheb
Email(s):
digvijaysinhkale88@gmail.com
DOI:
10.5958/2231-5713.2021.00004.0 
Address:
Kale Digvijaysinh Ramesh1*, Khedkar Amol Navnath1, Pawar Jaydeep Babasaheb2
1H.S.B.P.V.T’s, G.O.I., Parikrama Diploma in Pharmaceutical Sciences, Kashti, Shrigonda, Ahmednagar, Maharashtra, India 414701.
2H.S.B.P.V.T’s, G.O.I., College of Pharmacy, Kashti, Shrigonda, Ahmednagar, Maharashtra, India 414701.
*Corresponding Author
Published In:
Volume - 11,
Issue - 1,
Year - 2021
ABSTRACT:
The treatment of peptic ulcer disease involves multi drug regimen which causes patient discomfort. Roxithromycin and Esomeprazole are successful agents used in the treatment of peptic ulcer disease, but are available as separate unit dosages. Roxithromycin has broad spectrum of antibacterial activity and previous literature shows it inhibits H. Pylori. Esomeprazole is unstable in acidic pH but a valued proton pump inhibitor. Therefore, a humble effort was made in this investigation, to formulate a tablet dosage form containing both these drugs. Core tablets containing esomeprazole and a floating type coat formulation containing Roxithromycin, compressed into a single unit were developed and prepared. A buoyant tablet where made to float over the surface of the gastric fluids and thereby increasing the gastric retention time (GRT) of the drugs like Roxithromycin, thereby increased bioavailability and hence therapeutic efficacy is might improve. Also, it was planned to evaluate such tablets for their various pre-compression and compression characteristics, in vitro drug release kinetics and stability of the dosage forms. The present study outlines a systematic approach for designing and development of Esomeprazole and Roxithromycin floating tablets to enhance the bioavailability and therapeutic efficacy of the drug in the peptic ulcer disease.
Cite this article:
Kale Digvijaysinh Ramesh, Khedkar Amol Navnath, Pawar Jaydeep Babasaheb. Formulation and in-vitro Evaluation of floating tablets of Antibiotics used in the treatment of Peptic ulcer. Asian J. Pharm. Tech. 2021; 11(1):18-26. doi: 10.5958/2231-5713.2021.00004.0
Cite(Electronic):
Kale Digvijaysinh Ramesh, Khedkar Amol Navnath, Pawar Jaydeep Babasaheb. Formulation and in-vitro Evaluation of floating tablets of Antibiotics used in the treatment of Peptic ulcer. Asian J. Pharm. Tech. 2021; 11(1):18-26. doi: 10.5958/2231-5713.2021.00004.0 Available on: https://ajptonline.com/AbstractView.aspx?PID=2021-11-1-4
REFERENCES:
1. Wilson CG, Washington N. Physiological Pharmaceutics: Biological Barriers to Drug Absorption, Horwood Ellis, Chichester, 1989; 47-70
2. Singh BM, Kim KH. Floating drug delivery systems: an approach to controlled drug delivery via gastric retention. Cont. J Rel. 2000; 63: 235–259.
3. Reddy LH, Murthy RH. Floating Dosage Systems in Drug Delivery, Crit. Rev. There. Drug Carr. Syst. 2002; 19(6): 553-585
4. Garg S, Sharma S. Gastro retentive Drug Delivery System, Business Briefing: Pharmatech. 2003; 160-166.
5. http://www.mayoclinic.com/health/peptic-ulcer/D/section3/ overview. dtd: 5/05/07
6. http://www.Clark.T.J.inc.com/bacterial_diseases/helicobacterpylori.htm.dtd: 20/06/07
7. http://www.mayoclinic.com/health/peptic/section4/causes.dtd: 24/03/07
8. Willemijnite A, Hoogerwerf, Pankaj J. Agents used for control of gastric acidity and treatment of peptic ulcers and gastro esophageal reflux disease. Chapter. 10 in; Goodman and Gilman’s The Pharmacological Basis of Therapeutics. Edtrs., Alfred Goodman Gilman. New York: McGraw-Hill, Medical publishing division. 2001; 1005-1011.
9. Finlayson NDC, Hayes PC, Simposon KJ. Dieases of the liver and bilary system. Chapter. 9 in; Principles and Practice of Medicine. 18thedn, Edtrs. ChristopherHas left, Edwin R. Chilvers, John A Hunter A. New York: Church Chill Livingstone. 1999; 631-637.
10. Floating Drug Delivery System: J of Current Pharmaceutical Research 2011; 7(1): 6-20.
11. Chawla G, Bansal AA.Means to address regional variability in intestinal drug absorption. Pharm Tech. 2003; 27: 50-68.
12. Machida Y, Inouye K, Tokumura T. Preparation and evaluation of intragastric buoyant preparations. Drug Design and Delivery. 1989; 4: 155-161.
13. Groning R, Heun G. Oral dosage forms with controlled gastrointestinal transit. Drug. Dev. Ind. Pharm. 1984; 10:527-539.
14. Burns SJ, Attwood D, Barnwell SG. Assessment of a dissolution vessel designed for use with floating and erodible dosage forms. Int J Pharm. 1998; 160: 213-218.
15. Sheth PR, Tossounian J. The Hydrodynamic ally Balanced System: A novel drug delivery system for oral use. Drug. Dev. Ind. Pharm. 1984;10 (2): 313-339.
16. http://www.medicinenet.com/script/main/atr.asp. dtd: 18/03/07
17. Streubel A, Siepmann J, Bomeier R. Floating matrix tabelet based on low density foam powder: effect of formulation and processing parameters on drug release. European Journal of Pharmaceuics. 2003; 18: 37-45
18. Abdul Sayeed, Hamed Mohiuddin. Mouth dissolving tablets: An Overview. International Journal of Research in Pharmaceutical and Biomedical Sciences. 2011; 2 (3): 959-970
19. United State Pharmacopoeia 24 NF 19, USP Convetions, Maryland, USA Rock Ville: 1985; 1941.
20. Indian Pharmacopoeia 2010, Vol-III. Govt of India, Ministry of Health and FamilyWelfare. Delhi: Controller of Publication. p. 2073-2075.
21. Indian Pharmacopoeia 2010, Vol-III. Govt of India, Ministry of Health and Family Welfare. Delhi: Controller of Publication. p.1295.
22. Brijesh SD, Avani FA, Patel MM. Gastroretentive drug delivery system of ranitidine hydrochloride: Formulation and In Vitro evaluation. AAPS Pharm Sci. Tech. 2004; 5 (2): (online).